Navigation Links
CaroGen Announces Publication of Therapeutic Vaccine Technology Research for Hepatitis B Virus
Date:8/17/2015

CaroGen Corporation, an emerging vaccine company, today announced the electronic publication of a research article entitled “Virus-Like Vesicle-Based Therapeutic Vaccine Vectors for Chronic Hepatitis B Virus Infection,” which appeared in the August online issue of the Journal of Virology.

The paper includes research conducted in the laboratories of Dr. John Rose and Dr. Michael Robek, both faculty at Yale University, with the virus-like vesicle (VLV) platform technology, and the results of preclinical vaccine candidates aimed for treatment of chronic hepatitis B virus (HBV) infection. It is the first publication that includes data from induction of immunogenicity and potential application of VLV-based vaccines using both acute and chronic animal models of HBV.

“The publication of this work is a major milestone for CaroGen, as it provides a peer-reviewed report of our proof-of-concept HBV vaccine studies to date,” said Dr. Bijan Almassian, CEO of CaroGen.

Chronic HBV infection is a condition that affects approximately 240 million individuals globally and causes an estimated 600,000 deaths per year.

“There is a clear need for new therapies for chronically infected individuals,” said Dr. Michael Robek, senior author of the research and faculty member in the department of pathology at Yale University. “With the virus-like vesicle technology and hepatitis B vaccine candidates under development, we are looking to deliver the needed balance of safety combined with induction of functional immune responses.”

The VLV technology was developed by Dr. John Rose, Yale University virologist and professor of pathology at the Yale School of Medicine, and was licensed by CaroGen in 2012.

Connecticut Innovations (CI) has been a key supporter of the company and this work has been received funding through the pre-seed fund and the Connecticut Bioscience Innovation Fund, managed by CI.

About CaroGen
CaroGen Corporation is an emerging vaccine company employing a virus-like vesicle (VLV) platform technology developed at Yale University School of Medicine and exclusively licensed for the development and commercialization of vaccines worldwide. The company is developing a portfolio of vaccine candidates with a lead vaccine program in chronic HBV infection – a pathogen of global concern and a leading cause of liver disease and cancer. http://www.carogencorp.com.

Contact:
CaroGen Corporation
Bijan Almassian (203) 230-8596
balmassian(at)carogencorp.com

Read the full story at http://www.prweb.com/releases/CaroGen/Research/prweb12906352.htm.


'/>"/>
Source: PRWeb
Copyright©2015 Vocus, Inc.
All rights reserved

Related biology technology :

1. Eiger BioPharmaceuticals Announces Key Operational Hires to Senior Management Team: Jim Welch, Chief Financial Officer; Jim Shaffer, Chief Business Officer
2. Immune Pharmaceuticals Announces Corporate Update; Second Quarter 2015 Financial Results and Highlights and Conference Call Details
3. PTC Therapeutics Announces Closing of $150 Million of Convertible Senior Notes
4. Echo Therapeutics, Inc. Provides Corporate Update and Announces Second Quarter 2015 Financial Results
5. Cepheid Announces CFO Change
6. Lee Biosolutions Announces Appointment of New President and Chief Operating Officer
7. LabStyle Innovations Announces 2015 Second Quarter Results
8. Whitehouse Laboratories Announces Participation at 14th Annual Contract Pharma Conference
9. aTyr Pharma Announces Second Quarter 2015 Operating Results
10. Soligenix Announces Recent Highlights and Second Quarter 2015 Financial Results
11. Aeterna Zentaris Announces Data and Safety Monitoring Board Scheduled to Complete Second Interim Analysis of the ZoptEC Phase 3 Trial in Endometrial Cancer in Early October
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/18/2018)... ... December 18, 2018 , ... Patients with early stages of breast cancer who ... post-treatment versus whole breast irradiation, a new study suggests. , Patients with early stage ... irradiation after removal of the cancerous tumor because there is a 30 to 40 ...
(Date:12/13/2018)... (PRWEB) , ... December 12, 2018 , ... ... other life science software solutions, announces the Limfinity® ML (Machine Learning) addition for ... trained machine learning models within Limfinity® solutions. In the module, trained models make ...
(Date:12/10/2018)... China and SAN DIEGO (PRWEB) , ... ... ... MabPlex International, Ltd., a fully integrated Contract Development and Manufacturing Organization (CDMO) ... development, process characterization, conjugation optimization, cGMP manufacturing, and aseptic fill finish solutions ...
(Date:12/5/2018)... ... December 05, 2018 , ... STRmix™ – sophisticated forensic software ... – has been used to convict a Wyoming man of third-degree sexual assault, a ... used STRmix™ to test for DNA on the couch cushions on which the sexual ...
Breaking Biology Technology:
(Date:12/13/2018)... ROCHELLE, Va. (PRWEB) , ... December 12, 2018 ... ... today that Dr. Vinod Shah, one of the firm’s prominent Expert Consultants, was ... Leader Award. The award recognizes leaders who are working in pharmaceutical science, technology, ...
(Date:12/13/2018)... ... 12, 2018 , ... Illumina, Kaiser Permanente, ResMed and Aetna were just a ... team-building and cooking events company has hosted an impressive guest list of Fortune 500 ... , Each group who visits receives a completely customized experience, right down to the ...
(Date:12/13/2018)... ... December 13, 2018 , ... Biocompare, ... documentary entitled “What Researchers Need to Know about Antibody Manufacturing” . This ... Research series. The goal of this film is to educate scientists about antibody ...
Breaking Biology News(10 mins):